Rocket suspends gene therapy trial

This is a news story, published by Yahoo Finance, that relates primarily to Rocket Pharmaceuticals, Inc. news.

drug discoveries news

For more drug discoveries news, you can click here:

more drug discoveries news

Yahoo Finance news

For more news from Yahoo Finance, you can click here:

more news from Yahoo Finance

About the Otherweb

Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about

FDA

. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest gene therapy field news, gene therapies news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!

gene therapy

Insider Trading & Hedge Fund Data, and Investment Newsletter From Insider Monkey

•

Health

Rocket Pharmaceuticals, Inc. (RCKT) Gene Therapy Trial Paused Following Patient Death

Summary

Nutrition label

84% Informative

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT ) suspended dosing in its Danon disease gene therapy trial after a patient developed fatal complications from capillary leak syndrome.

The patient’s death has raised concerns among analysts about the unpredictable risks of gene therapies.

RCKT reported $318.2 million in cash, providing financial runway into 2027 .

VR Score

Informative language

Neutral language

Article tone

formal

Language

English

Language complexity

Offensive language

not offensive